Date
- 2026 (1)
- 2025 (26)
- 2024 (41)
- 2023 (48)
- 2022 (26)
- 2021 (101)
- 2020 (61)
- 2019 (126)
- 2018 (40)
- 2017 (22)
- 2016 (24)
- 2015 (14)
- 2014 (22)
- 2013 (8)
- 2012 (3)
- 2010 (2)
- 2009 (11)
- 2008 (5)
- 2007 (12)
- 2006 (10)
- 2005 (14)
- 2004 (5)
- 2003 (2)
- 2002 (6)
- 2001 (3)
- 2000 (12)
- 1999 (5)
- 1998 (4)
- 1997 (1)
- 1996 (7)
- 1995 (2)
- 1994 (6)
- 1993 (6)
- 1991 (20)
Sponsor content
696 result(s) found, displaying 61 to 70
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Australian public assessment report (AusPar)Beyfortus (nirsevimab) has been approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season. It is also for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Lantus Cartridge.